US 12,220,455 B2
Coronavirus vaccine compositions and methods
Sean Michael Sullivan, Escondido, CA (US); Daiki Matsuda, San Diego, CA (US); Kiyoshi Tachikawa, San Diego, CA (US); Padmanabh Chivukula, San Diego, CA (US); Priya Prakash Karmali, San Diego, CA (US); Jared Henry Davis, Poway, CA (US); Yanjie Bao, San Diego, CA (US); and Amit Sagi, San Diego, CA (US)
Assigned to Arcturus Therapeutics, Inc., San Diego, CA (US)
Filed by Arcturus Therapeutics, Inc., San Diego, CA (US)
Filed on Jun. 30, 2023, as Appl. No. 18/345,893.
Application 18/345,893 is a continuation of application No. 17/196,889, filed on Mar. 9, 2021, granted, now 11,744,887.
Claims priority of provisional application 63/073,900, filed on Sep. 2, 2020.
Claims priority of provisional application 62/987,191, filed on Mar. 9, 2020.
Prior Publication US 2024/0115691 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/215 (2006.01); A61K 9/51 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 47/10 (2017.01); A61K 47/20 (2006.01); A61K 47/26 (2006.01); C07K 14/005 (2006.01); C07K 14/18 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01)
CPC A61K 39/215 (2013.01) [A61K 9/5123 (2013.01); A61K 39/12 (2013.01); A61K 47/10 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01); C07K 14/005 (2013.01); C07K 14/1808 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 2039/53 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01); C12N 2770/36122 (2013.01); C12N 2770/36134 (2013.01); C12N 2830/42 (2013.01); C12N 2830/50 (2013.01)] 33 Claims
 
1. A nucleic acid molecule comprising:
(i) a first polynucleotide encoding one or more viral replication proteins, wherein the first polynucleotide is codon-optimized as compared to a wild-type polynucleotide encoding the one or more viral replication proteins, and wherein the first polynucleotide comprises a sequence having at least 80% identity to the sequence of SEQ ID NO:72; and
(ii) a second polynucleotide comprising a transgene encoding an antigenic protein or a fragment thereof, wherein the antigenic protein is a coronavirus protein encoded by a sequence having at least 90% identity to the sequence of SEQ ID NO: 122.